Dr Farhad Soheilmoghaddam

Postdoctoral Research Fellow-Biomat

Australian Institute for Bioengineering and Nanotechnology


With an ageing population, maintaining productivity and participation in society as we age represents one of global greatest challenges in the next 50 years. Whilst the prospect of autologous perivascular stem cell-based products for repairing musculoskeletal tissue damage or deficits has tremendous potential for improving the quality of life of Aging societies, this potential will remain largely unrealised if we cannot address their acquisition of early senescence in culture. My research focuses on synthesising novel glycan-binding polymers that can mimic the function of lectins to invoke a perivascular stem cells adhesion, spreading, and expansion in the multipotent state on substrates mechanically matched to the perivascular niche.

In line with my background as a Materials Engineer, I have also been working on fabrication of a robust, reliable and scalable 3D printed scaffold for functional organ replacement using our developing polymer-based bioinks. These novel bioinks that synthesised using our high-throughput, automatable system enables the bioprinting of an individual’s ‘own’ multicellular organ for use in patient-specific drug or biotherapeutic screening discovery, and ultimately functional organ replacement.

I completed my PhD at The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) under the supervision of Prof. Justin Cooper-White and A/Prof Allison Pettit, in the development of biomimetic multilayered nano-fibrous scaffolds for guided bone regeneration.

Research Interests

  • Developing 3D bioprinting platforms to model and study the human perivascular niche

Research Impacts

Our projected outcomes from this research are significant, innovative, and impactful, adressing an “Advanced Manufacturing" challenges of “specialised high-performance materials". We will offer a possible path to such patient-specific regenerative solutions through the removal of fundamental materials design and processing roadblocks that we will focus on in this proposal. My project will furthermore lead to a higher quality of life in those requiring cell therapy through the provision of higher quality, higher functioning bio-printed starting points in the tissue engineering pipeline.

Translation of cells into functional tissue engineered products, enabling Australia to play a substantive role in the global cell therapy market, expected to reach $330 million by 2020, at a compound annual growth rate of ~40% from 2015 to 2020, will have significant economic impact and benefit. The new linkages that arise from these projects will have clear benefits for the Australian scientific and industrial communities, including stimulating local expertise and enhanced international reputation.


  • Doctor of Philosophy, The University of Queensland


View all Publications


Book Chapter

Journal Article